Bayer AG
XETRA:BAYN
Bayer AG
XETRA:BAYN
Price:
26.9 EUR
-0.26%
Market Closed
Updated:
Apr 26, 2024
P/S
Price to Sales
Price to Sales
0.6
Current
1
Median
2.3
Industry
Lower
than median
Lower
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=0.6
Market Cap
/
26.4B
Revenue
47.6B
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| DE |
|
Bayer AG
XETRA:BAYN
|
26.4B EUR | 0.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
688.2B USD | 20.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.6 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
353.4B USD | 4.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.9B USD | 5.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.4B GBP | 5.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
184B CHF | 4.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
174.4B CHF | 3 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
0.6
2-Years Forward
P/S
0.5
3-Years Forward
P/S
0.6
You don't have any saved screeners yet
